|
NR 10-12/2007
|
|
|
|
|
|
|
|
|
Pegaptanib sodium w
leczeniu neowaskularyzacji podsiatkówkowych wtórnych do
zwyrodnienia plamki związanego z wiekiem. Wyniki roczne
Pegaptanib sodium in
treatment of choroidal neovascularization secondary to
age-related macular degeneration. One year results
Halina Wykrota, Urszula Gajdzik-Gajdecka,
Krzysztof Trzciąkowski, Magdalena Smużyńska
Samodzielny Publiczny Szpital Kliniczny Nr 5 Śląskiego
Uniwersytetu Medycznego w Katowicach
Dyrektor: prof. dr hab. n. med. Ariadna Gierek-Łapińska |
|
|
| Summary: |
Purpose:
Prospective, noncomparative (nonrandomized, uncontrolled),
consecutive interventional case series study - to
evaluate the efficacy of intravitreal pegaptanib sodium
in the treatment of choroidal neovascularization due to
age-related macular degeneration in treatment-naive
patients.
Material and methods: 38 eyes of 38 patients were
treated with intravitreal pegaptanib. All angiographic
subtypes of lesions were qualified to the treatment.
Intravitreal injections were performed every 6 weeks at
the discretion of the treating ophthalmologist.
Retreatment criteria were based on evaluation of
presence of submacular fluid and/or increase in macular
thickness seen in OCT, new retinal hemorrhage, and loss
of visual acuity (VA).
Results: The VA outcomes were assessed at 48-th
week of the study. The mean change in VA for all lesions
was a loss of 9.4 ETDRS letters. Percent of patients
losing less than 15 ETDRS letters in predominantly
classic subgroup was 68%, minimally classic – 65% and
pure occult – 72%. 7% of patients gained more than 1
ETDRS lines of VA whereas 2% more than 3 ETDRS lines.
8.5% of patients lost 30 and more ETDRS letters at 48-th
week of the study. Results were better for smaller (<4
DA) lesions, eyes with better (> 54 ETDRS letters)
baseline VA and for pure occult lesions.
Conclusions: Pegaptanib sodium effectively
preserve vision in approximately 70% of patients with
wet AMD in 1-year period of observation. Eyes with more
advanced lesions seen at baseline have an increased risk
of worse VA outcomes. |
| Słowa kluczowe: |
neowaskularyzacje
podsiatkówkowe, zwyrodnienie plamki związane z wiekiem,
pegaptanib sodu, czynnik wzrostu śródbłonka naczy. |
| Key words: |
choroidal
neovascularization age-related macular degeneration,
pegaptanib sodium, vascular endothelial growth factor. |
|
|
|
|
|
|
